Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III, multi-center, randomized, multiple-dose, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of abuse deterrent ELI-200 for the treatment of adults with moderate to severe pain following surgery.

Next Previous
Search
Trial Profile

A phase III, multi-center, randomized, multiple-dose, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of abuse deterrent ELI-200 for the treatment of adults with moderate to severe pain following surgery.

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Jul 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Oxycodone/naltrexone (Primary)
  • Indications Postoperative pain
  • Focus Therapeutic Use

    • Most Recent Events

    • 15 Jul 2016 According to Elite Pharmaceuticals media release, the U.S. Food and Drug Administration (the "FDA") has issued a Complete Response Letter (the "CRL") regarding the New Drug Application (the "NDA") for SequestOx™ (oxycodone hydrochloride and naltrexone hydrochloride). The CRL determined that the NDA was not ready for approval in its present form.
    • 09 May 2016 According to an Elite Pharmaceuticals media release, the New Drug Application (NDA) for ELI-200 (SequestOX) has been accepted and granted priority review by the FDA with target action date under the Prescription Drug User Fee Act (PDUFA) of July 14, 2016.
    • 09 Feb 2016 Elite Pharmaceuticals has submitted a 505(b)(2) NDA to the US FDA, according to a company media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top